Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How Was Korea Different In Handling COVID-19 Situation?

Officials Outline Policy Approach

Executive Summary

South Korea authorities talk to foreign media about the country's experience and successes in dealing with the COVID-19 situation, lessons learned, preparations being made to return to everyday life and R&D activity.

You may also be interested in...



Korea To Keep Tight Policy Focus On COVID-19 This Year

South Korea is ramping up policy and financial support in its continuing efforts to control COVID-19, with new drugs and vaccines set to benefit amid broader infectious disease control measures. 

APAC Podcast: Virus Industry Impact, China Vaccines, Remdesivir Deals, Korea SitRep

Join the Pink Sheet and Scrip's Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.

GC Pharma Aiming To Outrun Rivals For COVID-19 Plasma Therapy

A South Korean pharma firm is set to soon begin pivotal clinical trials for a hyperimmune globulin for the treatment of COVID-19 patients and plans to commercialize the product this year, with a hope of outrunning rivals including Takeda.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS142203

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel